Optimizing Enfortumab Vedotin & Pembrolizumab for Urothelial Cancer | Oncotarget скачать в хорошем качестве

Optimizing Enfortumab Vedotin & Pembrolizumab for Urothelial Cancer | Oncotarget

Oncotarget #published this #trending review on June 17, 2025 in Volume 16, entitled “Optimizing enfortumab vedotin plus pembrolizumab therapy" by #researchers from Departements de Médecine Oncologique, Gustave Roussy F-94805, Villejuif, France; Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon; Department of Urology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon. #cancer #urothelialcancer #bladdercancer #review #research #openaccess #openscience #peerreview #journal #publication #publishing #meded DOI - https://doi.org/10.18632/oncotarget.28741 Correspondence to - Elias Antoine Karam - [email protected] Abstract Often associated with a poor prognosis, advanced urothelial carcinoma (aUC) has progressed to muscle-invasive or metastatic stages. Traditionally, chemotherapy has been the primary treatment for aUC, though its effectiveness in advanced stages remains limited. Recent developments have introduced promising therapies, notably the combination of enfortumab vedotin with pembrolizumab, which is now recommended as the first-line therapy following the EV-302 trial results. This combination has demonstrated significant improvements in survival rates. This review aims to explore the evolution of treatment strategies for aUC, emphasizing the shift towards immunotherapy and targeted therapies, and discusses the potential for optimized treatment algorithms to improve patient outcomes. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/e... Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, advanced urothelial carcinoma (aUC), enfortumab vedotin, pembrolizumab, treatment strategies, bladder cancer About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube -    / @oncotargetjournal   LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJz... Media Contact [email protected] 18009220957